Compound Heterozygous FKTN Variants in a Patient with Dilated Cardiomyopathy Led to an Aberrant &alpha;-Dystroglycan Pattern

Erich und Hanna Klessmann-Institut für Kardiovaskuläre Forschung und Entwicklung, Klinik für Thorax- und Kardiovaskularchirurgie, Herz und Diabeteszentrum NRW, Universitätsklinikum der Ruhr-Universität Bochum, Georgstr. 11, 32545 Bad Oeynhausen, Germany

Zentrum für Angeborene Herzfehler, Herz und Diabeteszentrum NRW, Universitätsklinikum der Ruhr-Universität Bochum, Georgstr. 11, 32545 Bad Oeynhausen, Germany

Kardiopathologie, Institut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Liebermeisterstraße 8, 72076 Tübingen, Germany

Authors to whom correspondence should be addressed.

Academic Editors: Vasileios Siokas and Efthimios Dardiotis

Int. J. Mol. Sci. 2022, 23(12), 6685; https://doi.org/10.3390/ijms23126685

Received: 13 May 2022 / Revised: 13 June 2022 / Accepted: 14 June 2022 / Published: 15 June 2022

(This article belongs to the Special Issue Genetic Basis and Epidemiology of Myopathies 2.0)

View Full-Text Download PDF

Browse Figures

Citation Export

Abstract

Fukutin encoded by FKTN is a ribitol 5-phosphate transferase involved in glycosylation of α-dystroglycan. It is known that mutations in FKTN affect the glycosylation of α-dystroglycan, leading to a dystroglycanopathy. Dystroglycanopathies are a group of syndromes with a broad clinical spectrum including dilated cardiomyopathy and muscular dystrophy. In this study, we reported the case of a patient with muscular dystrophy, early onset dilated cardiomyopathy, and elevated creatine kinase levels who was a carrier of the compound heterozygous variants p.Ser299Arg and p.Asn442Ser in FKTN. Our work showed that compound heterozygous mutations in FKTN lead to a loss of fully glycosylated α-dystroglycan and result in cardiomyopathy and end-stage heart failure at a young age. View Full-Text

Keywords: cardiogenetics; cardiomyopathy; dystroglycanopathy; fukutin; heart failure

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplementary File 1:
ZIP-Document (ZIP, 180 KiB)

Share and Cite

MDPI and ACS Style

Gaertner, A.; Burr, L.; Klauke, B.; Brodehl, A.; Laser, K.T.; Klingel, K.; Tiesmeier, J.; Schulz, U.; Knyphausen, E.z.; Gummert, J.; Milting, H. Compound Heterozygous FKTN Variants in a Patient with Dilated Cardiomyopathy Led to an Aberrant α-Dystroglycan Pattern. Int. J. Mol. Sci. 2022, 23, 6685. https://doi.org/10.3390/ijms23126685

AMA Style

Gaertner A, Burr L, Klauke B, Brodehl A, Laser KT, Klingel K, Tiesmeier J, Schulz U, Knyphausen Ez, Gummert J, Milting H. Compound Heterozygous FKTN Variants in a Patient with Dilated Cardiomyopathy Led to an Aberrant α-Dystroglycan Pattern. International Journal of Molecular Sciences. 2022; 23(12):6685. https://doi.org/10.3390/ijms23126685

Chicago/Turabian Style

Gaertner, Anna, Lidia Burr, Baerbel Klauke, Andreas Brodehl, Kai Thorsten Laser, Karin Klingel, Jens Tiesmeier, Uwe Schulz, Edzard zu Knyphausen, Jan Gummert, and Hendrik Milting. 2022. "Compound Heterozygous FKTN Variants in a Patient with Dilated Cardiomyopathy Led to an Aberrant α-Dystroglycan Pattern" International Journal of Molecular Sciences 23, no. 12: 6685. https://doi.org/10.3390/ijms23126685

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Compound Heterozygous FKTN Variants in a Patient with Dilated Cardiomyopathy Led to an Aberrant α-Dystroglycan Pattern

Abstract

Supplementary Material

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI